10:59 AM EDT, 04/10/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) , down 5.5% on last look, on Thursday said its subsidiary BriaPro is developing high affinity antibodies to B7-H3, a key factor in cancer progression. BriaPro, which has filed provisional US patent applications for the technology, will also file an international patent application under the Patent Cooperation Treaty.

BriaPro plans to develop anti-B7-H3 antibodies for multiple cancer indications and plans to incorporate them into its Bria-TILsRx platform, which is designed to redirect and activate T cells within the tumor microenvironment.

"B7-H3 is overexpressed in a broad range of solid tumors (including prostate, lung, breast, pancreatic, and ovarian cancers) while showing limited expression in normal tissues. This makes it an ideal target to selectively activate tumor infiltrating lymphocytes and drive potentially potent anti-tumor responses with reduced risk of off-target toxicity," said BriaPro Chief Scientific Officer.

The company's shares are now down $0.32, to $5.52, on the Toronto Stock Exchange.

Price: 5.52, Change: -0.32, Percent Change: -5.48